NCT03269019

Thrombotic Biomarkers to Predict Thrombosis in Heparin-induced Thrombocytopenia

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 200 (estimated)
• Sponsor: Wuhan Asia Heart Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Heparin induced thrombocytopenia (HIT) is a kind of catastrophic thrombotic complications after the application of heparin. If HIT without treatment, death rate is as high as 30% to 50%. Early diagnosis of HIT and prevention of thrombosis is very important. This study is planned to assess the use of thrombotic biomarkers in patients with HIT, including thrombin-antithrombin complex, d-dimer, fibrin degradation products and Thrombelastograghy monitoring . These biomarkers are monitored in 5-14 days post-operation to assess the risk of thrombosis in HIT patients. All patients were followed up for 30 days, and clinical outcomes, including new thrombus and death, were recorded during follow-up.

Conditions

• Heparin-Induced Thrombocytopenia
• Thrombosis
• Biomarkers

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	HIT with thrombosis	Testing thrombin-antithrombin complex, d-dimer, fibrin degradation products and Thrombelastograghy.

Timeline

• Start date: 2017-11-20
• Primary completion: 2019-08-19
• Completion: 2019-12-31
• First posted: 2017-08-31
• Last updated: 2017-08-31